MDxHealth (MDXH) Expected to Announce Quarterly Earnings on Wednesday

MDxHealth (NASDAQ:MDXH) is expected to issue its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.1447) per share and revenue of $30.8920 million for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

MDxHealth (NASDAQ:MDXH) last released its earnings results on Friday, February 27th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.04). MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 31.07%.The business had revenue of $29.55 million during the quarter, compared to the consensus estimate of $26.05 million. On average, analysts expect MDxHealth to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MDxHealth Price Performance

NASDAQ MDXH opened at $1.99 on Tuesday. The company’s 50 day simple moving average is $2.58 and its 200 day simple moving average is $3.31. MDxHealth has a 12 month low of $1.70 and a 12 month high of $5.33. The company has a market capitalization of $98.51 million, a P/E ratio of -2.97 and a beta of 1.60.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of MDxHealth in a report on Friday, March 27th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.75.

Institutional Trading of MDxHealth

Large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. bought a new stake in MDxHealth in the fourth quarter worth approximately $301,000. AlphaCentric Advisors LLC bought a new stake in MDxHealth in the fourth quarter worth approximately $268,000. Susquehanna International Group LLP bought a new stake in MDxHealth in the third quarter worth approximately $264,000. Hudson Bay Capital Management LP grew its position in MDxHealth by 271.9% in the fourth quarter. Hudson Bay Capital Management LP now owns 55,658 shares of the company’s stock worth $199,000 after acquiring an additional 40,692 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp bought a new stake in MDxHealth in the fourth quarter worth approximately $164,000.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.